Cargando…

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib

Carfilzomib, a second-generation proteasome inhibitor, has significantly improved the survival rate of multiple myeloma (MM) patients, but its clinical application is still restricted by drug resistance and cardiotoxicity. Here, we identified a novel proteasome inhibitor, D395, and assessed its effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Xuxing, Wu, Chao, Lei, Meng, Yan, Qing, Zhang, Haoyang, Zhang, Lina, Wang, Xueyuan, Yang, Ye, Li, Jianyong, Zhu, Yongqiang, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087809/ https://www.ncbi.nlm.nih.gov/pubmed/33931582 http://dx.doi.org/10.1038/s41419-021-03701-z

Ejemplares similares

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma
por: Ikoma, Takenori, et al.
Publicado: (2019)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma
por: Zhou, Hui, et al.
Publicado: (2020)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
por: Efentakis, Panagiotis, et al.
Publicado: (2020)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
por: Chen-Scarabelli, Carol, et al.
Publicado: (2017)

Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator–Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway
por: Chen, Ying, et al.
Publicado: (2022)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
por: Lee, Min Jae, et al.
Publicado: (2019)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice
por: Park, Ji Eun, et al.
Publicado: (2017)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017)

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2022)

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin
por: Efentakis, Panagiotis, et al.
Publicado: (2021)

Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Buck, Benjamin, et al.
Publicado: (2022)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
por: Han, Bo, et al.
Publicado: (2015)

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
por: Tundo, Grazia Raffaella, et al.
Publicado: (2022)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Targeted treatments for multiple myeloma: specific role of carfilzomib
por: Sugumar, Dhivya, et al.
Publicado: (2015)

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
por: Baranowska, Katarzyna, et al.
Publicado: (2016)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
por: Steiner, Raphael E, et al.
Publicado: (2017)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
por: Yang, Jenny Z., et al.
Publicado: (2021)

TRPV2-induced Ca(2+)-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
por: Bai, Hua, et al.
Publicado: (2018)

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE
por: Slørdahl, T. S., et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis
por: Tantawy, Marwa, et al.
Publicado: (2021)

Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma
por: Tantawy, Marwa, et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ueotmbhqi5r777pmvsii509qtn